Patient-reported quality of life did not differ significantly between the two treatment groups, according to Dr. Coleman. Not surprisingly, those given bevacizumab were less likely to receive more of that agent or another anti-angiogenic agent as the next line of therapy after progression.
Data for the second co-primary endpoint, the overall survival impact of secondary cytoreductive surgery, are currently pending, he said.